Bevacizumab for the management of diabetic macular edema

doi:10.4239/wjd.v4.i2.19

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 2

This Article

(0)

(7662)

(30)

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Topic Highlight

World J Diabetes. Apr 15, 2013; 4(2): 19-26
Published online Apr 15, 2013. doi: 10.4239/wjd.v4.i2.19

Full Size Figure Download Figure

Figure 4 Cost per injection of ranibizumab (LucentisTM Genentech, United States), in the treatment of diabetic macular edema, compared with the cost per injection of bevacizumab (Avastin, Roche, United States). The cost is, in average, 20-fold higher in for treatment with ranibizumab than bevacizumab. Depending on the country, this difference may vary from 20× to 50×.

Citation: Stefanini FR, Arevalo JF, Maia M. Bevacizumab for the management of diabetic macular edema. World J Diabetes 2013; 4(2): 19-26
URL: https://www.wjgnet.com/1948-9358/full/v4/i2/19.htm
DOI: https://dx.doi.org/10.4239/wjd.v4.i2.19

Stefanini FR, Arevalo JF, Maia M. Bevacizumab for the management of diabetic macular edema. World J Diabetes 2013; 4(2): 19-26 [PMID: 23593532 DOI: 10.4239/wjd.v4.i2.19]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.